Australia markets open in 5 hours 24 minutes

Vitura Health Limited (VIT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0940-0.0020 (-2.08%)
At close: 03:59PM AEST
Full screen
Previous close0.0960
Bid0.0950 x N/A
Ask0.0980 x N/A
Day's range0.0940 - 0.0960
52-week range0.0750 - 0.6000
Avg. volume692,347
Market cap54.132M
Beta (5Y monthly)0.18
PE ratio (TTM)4.70
EPS (TTM)0.0200
Earnings date20 Aug 2024 - 25 Aug 2024
Forward dividend & yield0.01 (10.64%)
Ex-dividend date04 Sept 2023
1y target estN/A
  • Simply Wall St.

    Could The Market Be Wrong About Vitura Health Limited (ASX:VIT) Given Its Attractive Financial Prospects?

    It is hard to get excited after looking at Vitura Health's (ASX:VIT) recent performance, when its stock has declined...

  • GlobeNewswire

    Cronos Enters Australian Cannabis Market

    TORONTO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited (“Vitura”) (ASX: VIT). Cronos owns approximately 10% of the common shares of Vitura, formerly known as Cronos Australia, and will supply cannabis for Vitura. “Supplying the Australian market, which has grown significantly in the past three

  • GlobeNewswire

    PharmAla Files Audited Financials for Year Ending August 31, 2023

    Highlights include Revenue Growth, Expansion of IP Licensing, and formation of Cortexa Joint VentureVANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to file its audited financial statements for the year ended on August 31, 2023. Following is a short list of th